Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 1999, p. 1294-1297, Vol. 43, No. 5
The Department of Laboratory Medicine,
Division of Clinical Microbiology, Karolinska Institute and
Karolinska Hospital, 171 76 Stockholm, Sweden,1
and Laboratory of Microbiology, The Rockefeller University,
New York, New York 100212
Received 13 August 1998/Returned for modification 29 January
1999/Accepted 10 February 1999
Two Since the early 1980s, isolates of
Klebsiella oxytoca have been recognized as clinically
significant and an indication for therapy (17). Clinical
isolates of Klebsiella spp. resistant to cefotaxime,
ceftazidime, or aztreonam have been increasingly reported (6, 12,
14). These bacteria can develop resistance to the newer
cephalosporins and aztreonam by acquisition of plasmid-located extended-spectrum In previous studies (27, 28), 11 clinical isolates of
K. oxytoca were found to be resistant to aztreonam and
cefuroxime (MIC of >16 µg/ml) but susceptible to cefotaxime,
ceftazidime, and imipenem (MICs of <4 µg/ml). The bacteria isolated
in these previous studies belonged to three subgroups based on their
plasmid profiles (27, 28). By isoelectric focusing, a
single, common Seven of the previously reported cefuroxime- and aztreonam-resistant
K. oxytoca isolates (27, 28) were further
investigated in the present study. One susceptible strain of
K. oxytoca isolated during the same period from a
patient in Karolinska Hospital was also included. E. coli DH5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Genetic Characterization of Resistance to Extended-Spectrum
-Lactams in Klebsiella oxytoca Isolates Recovered
from Patients with Septicemia at Hospitals in the Stockholm
Area
![]()
ABSTRACT
Top
Abstract
Text
References
-lactamase gene regions were characterized by DNA sequencing
in eight clinical isolates of Klebsiella oxytoca. The
blaOXY-2a region encoded a
-lactamase nearly
identical to OXY-2 (one amino acid residue substituted) and
conferred aztreonam and cefuroxime resistance on the K. oxytoca isolates. Overproduction of OXY-2a was caused by a G-to-A
substitution of the fifth nucleotide in the
10 consensus sequence of
blaOXY-2a. The
blaOXY-1a was identified in a susceptible
strain, and the OXY-1a enzyme differed from OXY-1 by two amino acid residues.
![]()
TEXT
Top
Abstract
Text
References
-lactamases (ESBLs) (7, 18,
25) or by mutations giving rise to the hyperproduction of
chromosomal
-lactamases (15). In wild-type
K. oxytoca, chromosomal
-lactamases are constitutively produced at low levels which are sufficient to affect
the organism's susceptibility to ampicillin, amoxicillin, carbenicillin, and ticarcillin (17). Overproduction of these
-lactamases, however, confers resistance to penicillins,
cephalosporins, and aztreonam (8); in most cases this
overproduction results from a mutation in the promoter region of the
-lactamase gene (9, 11). Molecular cloning
and DNA sequencing have shown that the chromosomal
-lactamase genes in K. oxytoca can be
divided into two main groups: blaOXY-1 and
blaOXY-2 (11). These two categories
of
-lactamase genes show 89.7% homology in DNA
sequences and belong to functional group 2be of the ESBLs
(4) and Ambler class A (1).
-lactamase with a pI of 5.25, designated
KH, was observed in the strains. The resistance could not be
transferred to Escherichia coli XAC and C600 by
transformation and conjugation, suggesting a chromosomal location for
the
-lactamase gene. Furthermore, the substrate profile
of the KH
-lactamase exhibited the hydrolysis of
aztreonam characteristic of the enzymes of the K. oxytoca OXY family (10, 28). The aim of the present
study was to characterize the genetic determinant for the ESBL produced
by the K. oxytoca isolates recovered from hospitalized
patients in the Stockholm area.
was the host for the cloning experiment. Plasmid
pACYC177 was used to construct cloning vector pLSK (low copy number,
single cloning site, and kanamycin resistance) (Table 1).
TABLE 1.
Bacterial strains and plasmids used in this study
All standard nucleic acid techniques were carried out essentially as
described by Ausubel et al. (2) and Sambrook et al. (20). Plasmid DNA was prepared by use of the Wizard Plus
Minipreps or Midipreps DNA purification system (Promega, Madison,
Wis.). Chromosomal DNA from the K. oxytoca
isolates was prepared according to the procedure of Wilson
(26). The quantity of recovered DNA was measured with a
GeneQuant RNA-DNA calculator (Pharmacia Biotech, Ltd.,
Cambridge, England). Plasmid DNA was introduced into
E. coli by transformation with
CaCl2-treated E. coli DH5
, as
recommended by Ausubel et al. (2). The DNA sequence was
determined by the dideoxy-chain termination method (21) with
an automated DNA-sequencing system (model 377; PE/ABI, Foster City,
Calif.). Nucleotide and deduced amino acid sequences were analyzed with
the GCG program (Genetics Computer Group, Madison, Wis.) and
Lasergene software (DNASTAR, Madison, Wis.).
Primer oligonucleotides are shown in Table
2. To detect the
blaOXY-1 gene, primers C and D were used to
generate a 668-bp amplicon. Primers L and M were employed to
detect blaOXY-2, producing a 723-bp PCR
fragment. Primers KHUBI and KHDBI were designed based on
blaOXY-2 (11) and
blaRBI (13) sequences, and these
primers were used to amplify the region covering the complete KH
-lactamase gene for cloning. Primers CYC7BI1 and CYC7BI2
were designed and employed to construct plasmid pLSK from plasmid
pACYC177 (19). The 5' nucleotides of the primers
KHUBI, KHDBI, CYC7BI1, and CYC7BI2 were modified to create a
BamHI restriction site (Table 2) in order to ligate the PCR
products. The PCR was made with a PCR reagent kit according to the
standard reaction recommended by the manufacturer (Perkin-Elmer Cetus,
Branchburg, N.J.). Therefore, 100 ng of the chromosomal DNA from each
of the K. oxytoca isolates and 40 pmol of each primer
were included in a 100-µl reaction mixture. PCR amplification was
performed in a DNA Thermal Cycler 480 (Perkin-Elmer Cetus) with the
following temperature profiles: 94°C for 5 min; 30 cycles of 94°C
for 1 min, 60 (for blaOXY-1) or 55°C (for
blaOXY-2) for 1 min, 72°C for 1 min, and
72°C for 5 min; and holding at 4°C (16).
|
The bacterial strains were grown in Luria-Bertani medium (Difco Laboratories, Detroit, Mich.) with aeration at 37°C. Kanamycin (Sigma, St. Louis, Mo.) was added at 50 µg/ml for selection and maintenance of pLSK plasmids. MICs of cefuroxime, aztreonam, cefotaxime, ceftazidime, and imipenem for the K. oxytoca isolates and E. coli transformants were determined by a microdilution method (27).
To determine whether the gene for KH
-lactamase is
located on a chromosome or a plasmid, one strain from each
plasmid subgroup of the K. oxytoca isolates was
studied. Chromosomal and plasmid DNA preparations from strains KH78
(group 1), KH11 (group 2), and NBL63 (group 3) were used as
templates for PCR amplification. Under the recommended
conditions, PCR products of 0.68 kb for blaOXY-1
(primer pair C-D) and 0.72 kb for blaOXY-2
(primer pair L-M) were obtained from the chromosomal DNA templates of
strains KH11, KH78, and NBL63. However, no PCR product was
obtained for blaOXY-1 (primer pair C-D) or for
blaOXY-2 (primer pair L-M) when the plasmid DNA
preparations of these strains were used as templates.
The region including the entire KH
-lactamase gene was
amplified from the chromosomal DNA of the K. oxytoca
isolates by using primers KHUBI and KHDBI. All PCR products from
strains KH11, KH66, KH78, and NBL63 were sequenced. The 1,062-bp
nucleotide sequence containing the
-lactamase gene from
strain KH11 and the deduced amino acid sequence are shown in Fig.
1. The 867-bp nucleotide sequence
(positions 147 to 1016) encoded a
-lactamase of 289 amino acid residues. The nucleotide sequence of this
-lactamase was nearly identical (99.8%) to that of the
wild-type OXY-2
-lactamase from K. oxytoca SL911 (11). The amino acid sequence of the
-lactamase was different from that of OXY-2 by only one
residue; Ala-13 (ABL Ala-10) (1) was absent in the enzyme
from strain KH11. On the basis of this high degree of similarity, KH
-lactamase was redesignated OXY-2a, and the KH
determinant was redesignated blaOXY-2a. The blaOXY-2a gene was preceded by a promoter, in
which TTGTCA and GATAAT were the
35 and
10
consensus sequences, respectively, and by a putative Shine-Dalgarno
sequence (AAGGAA). The nucleotide and amino acid sequences
of the
-lactamase genes and proteins of strains KH78 and
NBL63 were identical to those of strain KH11. The
-lactamase from the susceptible K. oxytoca strain KH66 was highly similar to wild-type OXY-1 in amino
acid sequence (99.3% identity), and the DNA equences encoding
the two proteins were also very similar (98.9% identity)
(9). The major difference between the proteins was that
Leu-262 (ABL Leu-261) and Glu-278 (ABL Glu-277) (1) in
OXY-1 were respectively substituted with Pro-262 (ABL 261) and Lys-278
(ABL 277) in KH66. Accordingly, the KH66 protein was designated OXY-1a.
|
The promoter regions from each of the eight K. oxytoca
isolates were sequenced. The promoters for the
-lactamase genes in all the isolates but KH66 had the
same consensus sequence as that for
blaOXY-2a in the strain KH11. Contrasting with
the promoter sequences of wild-type blaOXY-2
(TTGTCA for
35 and GATAGT for
10), the
blaOXY-2a promoters had a substitution (G
A)
of the fifth base in the
10 consensus sequence. The promoter of
blaOXY-1a in KH66 was identical to that of
wild-type blaOXY-1 (9).
The DNA fragment containing the replication origin and kanamycin
resistance gene in plasmid pACYC177 was PCR amplified by using the
primers CYC7BI1 and CYC7BI2. After digestion with BamHI, the
fragment was ligated with BamHI digests of
PCR-generated blaOXY-2a and
blaOXY-1a regions from Klebsiella
strains KH11 and KH66 to form recombined plasmids pLSKSW-7
and pLSKSW-8, respectively. The two plasmids were then
transformed into E. coli DH5
for the expression of
resistance to
-lactam antibiotics. The E. coli (pLSKSW-7) transformant and K. oxytoca KH11
showed similar antibiograms which indicated resistances to
aztreonam and cefuroxime and intermediate susceptibilities or
susceptibilities to cefotaxime, ceftazidime, and imipenem (Table
3). The E. coli
(pLSKSW-8) transformant and K. oxytoca KH66 similarly
displayed no significant resistances to the
-lactam antibiotics
tested (Table 3).
|
In the present study, by PCR-based cloning and sequencing techniques,
the chromosomally encoded OXY-2a was confirmed to be responsible for
-lactam resistance in the K. oxytoca isolates recovered from patients in the Stockholm area during 1987 (27, 28). The high identities of the OXY-2a coding regions and
promoter sequences in the K. oxytoca strains
suggest a common origin for the
-lactam-resistant
K. oxytoca isolates. The mutation observed in the
blaOXY-2a promoters may have resulted in
the overexpression of this
-lactamase, thereby
conferring resistance to
-lactam antibiotics on K. oxytoca. Similar findings have been reported by others (3, 8,
9, 17, 22-24).
Of the two substitutions observed in OXY-1a, one of them
(Pro-261) is located in a hydrophobic pocket and the other
(Lys-277) is quite close to the homologous active site
(Asp-276) of TEM
-lactamases (5).
In this study, the primers specific to OXY-1 and OXY-2 cross-amplified. This may have been caused by our use of a large amount of template DNA and the high homology of the two genes. This cross-amplification suggests that PCR conditions should be carefully established. The parallel PCRs for blaOXY-1 and blaOXY-2 should be set with the intention of differentiating the two genes. On the other hand, PCR might be performed with one of the primer pairs, and the PCR product might be directly sequenced to identify the genes.
The effort to construct a recombinant plasmid by ligating two PCR-generated DNA fragments was successful and demonstrated a simple, fast, and straightforward approach for cloning.
Nucleotide sequence accession numbers. The nucleotide sequences described in this paper have been submitted to EMBL-GenBank under accession no. Y17714 for blaOXY-2a and no. Y17715 for blaOXY-1a.
| |
ACKNOWLEDGMENTS |
|---|
We thank Robyn T. Bilinski for the valuable effort she made in the preparation of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Box 152, The Rockefeller University, 1230 York Ave., New York, NY 10021. Phone: (212) 327-8278. Fax: (212) 327-8688. E-mail: wus{at}rockvax.rockefeller.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ambler, R. P., A. F. Coulson, J. M. Frere, J. M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276:269-270. |
| 2. | Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1992. Short protocols in molecular biology. John Wiley, New York, N.Y. |
| 3. | Buirma, R. J., A. M. Horrevorts, and J. H. Wagenvoort. 1991. Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals. The 1990 Dutch surveillance study. Scand. J. Infect. Dis. Suppl. 78:35-44[Medline]. |
| 4. |
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamases and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 5. |
Caniça, M. M.,
N. Caroff,
M. Barthélémy,
R. Labia,
R. Krishnamoorthy,
G. Paul, and J.-M. Dupret.
1998.
Phenotypic study of resistance of -lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
Antimicrob. Agents Chemother.
42:1323-1328 |
| 6. |
Chanal, C. M.,
D. L. Sirot,
A. Petit,
R. Labia,
A. Morand,
J. L. Sirot, and R. A. Cluzel.
1989.
Multiplicity of TEM-derived -lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids.
Antimicrob. Agents Chemother.
33:1915-1920 |
| 7. |
Chardon, H.,
T. Fosse,
R. Labia,
M. H. Nicolas,
C. Poyart-Salmeron,
J. Sirot,
D. Sirot, and M. Vernon.
1993.
Multifactorial analysis of the phenotypes for -lactams of 1044 Escherichia coli strains.
Pathol. Biol. (Paris)
41:337-342[Medline].
|
| 8. |
Fournier, B.,
G. Arlet,
P. H. Lagrange, and A. Philippon.
1994.
Klebsiella oxytoca: resistance to aztreonam by overproduction of the chromosomally encoded -lactamase.
FEMS Microbiol. Lett.
116:31-36[Medline].
|
| 9. |
Fournier, B.,
C. Y. Lu,
P. H. Lagrange,
R. Krishnamoorthy, and A. Philippon.
1995.
Point mutation in the Pribnow box, the molecular basis of -lactamase overproduction in Klebsiella oxytoca.
Antimicrob. Agents Chemother.
39:1365-1368[Abstract].
|
| 10. |
Fournier, B., and P. H. Roy.
1997.
Variability of chromosomally encoded -lactamases from Klebsiella oxytoca.
Antimicrob. Agents Chemother.
41:1641-1648[Abstract].
|
| 11. |
Fournier, B.,
P. H. Roy,
P. H. Lagrange, and A. Philippon.
1996.
Chromosomal -lactamase genes of Klebsiella oxytoca are divided into two main groups, blaOXY-1 and blaOXY-2.
Antimicrob. Agents Chemother.
40:454-459[Abstract].
|
| 12. |
Gutmann, L.,
M. D. Kitzis,
D. Billot-Klein,
F. Goldstein,
G. Tran Van Nhieu,
T. Lu,
J. Carlet,
E. Collatz, and R. Williamson.
1988.
Plasmid-mediated -lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam.
Rev. Infect. Dis.
10:860-866[Medline].
|
| 13. | Kimura, K., Y. Arakawa, S. Ohsuka, H. Ito, K. Suzuki, H. Kurokawa, N. Kato, and M. Ohta. 1996. Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates. Antimicrob. Agents Chemother. 40:1988-1994[Abstract]. |
| 14. | Knothe, H., P. Shah, V. Krcmery, M. Antal, and S. Mitsuhashi. 1983. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11:315-317[Medline]. |
| 15. |
Labia, R.,
A. Morand,
M. Guionie,
M. Heintz, and J. S. Pitton.
1986.
Klebsiella oxytoca -lactamases: study of their action on 3d-generation cephalosporins.
Pathol. Biol. (Paris)
34:611-615[Medline].
|
| 16. |
Liu, Y.,
B. J. Mee, and L. Mulgrave.
1997.
Identification of clinical isolates of indole-positive Klebsiella spp., including Klebsiella planticola, and a genetic and molecular analysis of their -lactamases.
J. Clin. Microbiol.
35:2365-2369[Abstract].
|
| 17. |
Livermore, D. M.
1995.
-Lactamases in laboratory and clinical resistance.
Clin. Microbiol. Rev.
8:557-584[Abstract].
|
| 18. |
Reig, R.,
C. Roy,
M. Hermida,
D. Teruel, and A. Coira.
1993.
A survey of beta-lactamases from 618 isolates of Klebsiella spp.
J. Antimicrob. Chemother.
31:29-35 |
| 19. |
Rose, R. E.
1988.
The nucleotide sequence of pACYC177.
Nucleic Acids Res.
16:356 |
| 20. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 21. |
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 |
| 22. | Shah, P. M., R. Asanger, and M. Kahan. 1991. Incidence of multi-resistance in gram negative aerobes from intensive care units of 10 German hospitals. Scand. J. Infect. Dis. 78(Suppl.):22-34. |
| 23. |
Sirot, D. L.,
F. W. Goldstein,
C. J. Soussy,
A. L. Courtieu,
M. O. Husson,
J. Lemozy,
M. Meyran,
C. Morel,
R. Perez,
C. Quentin-Noury,
M. E. Reverdy,
J. M. Scheftel,
M. Rosenbaum, and Y. Rezvani.
1992.
Resistance to cefotaxime and seven other -lactams in members of the family Enterobacteriaceae: a 3-year survey in France.
Antimicrob. Agents Chemother.
36:1677-1681 |
| 24. | Snydman, D. R. 1991. Clinical implications of multi-drug resistance in the intensive care unit. Scand. J. Infect. Dis. 78(Suppl.):54-63. |
| 25. | Venezia, R. A., F. J. Scarano, K. E. Preston, L. M. Steele, T. P. Root, R. Limberger, W. Archinal, and M. A. Kacica. 1995. Molecular epidemiology of an SHV-5 extended-spectrum beta-lactamase in enterobacteriaceae isolated from infants in a neonatal intensive care unit. Clin. Infect. Dis. 21:915-923[Medline]. |
| 26. | Wilson, K. 1987. Preparation of genomic DNA from bacteria, p. 2.4.1-2.4.5. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol. 1. Wiley Interscience, Brooklyn, N.Y. |
| 27. |
Wu, S. W.,
K. Dornbusch,
E. Goransson,
U. Ransjo, and G. Kronvall.
1991.
Characterization of Klebsiella oxytoca septicaemia isolates resistant to aztreonam and cefuroxime.
J. Antimicrob. Chemother.
28:389-397 |
| 28. |
Wu, S. W.,
K. Dornbusch,
M. Norgren, and G. Kornvall.
1992.
Extended spectrum beta-lactamase from Klebsiella oxytoca, not belonging to the TEM or SHV family.
J. Antimicrob. Chemother.
30:3-16 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»